Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Krikor who wrote (1748)	9/19/2000 9:38:11 PM
From: yosid	Respond to of 1754

My understanding is that the reexamination is complete. There may be court litigation to follow, but VISX currently has the patent. We all are awaiting the content of the amended 388, as it will be released by the PTO.

To: Krikor who wrote (1748)	9/20/2000 11:41:35 AM
From: Ram Seetharaman	Respond to of 1754

From H&Q - VISX, Inc. (EYE) $29.81 - $1.8B mkt cap: '388 Patent Reexamination - What Does this Mean for VISX?; Reiterate BUY The US Patent and Trademark Office (PTO) issued a reexamination certificate of the '388 patent, upholding and strengthening VISX's key method patent. The PTO had previously notified VISX that it would issue the certificate. Implications are that VISX has the strongest basis ever on which to sue alleged infringers such as Bausch & Lomb and Nidek, should VISX choose to do so ("no comment" from VISX). No legal result is likely for a year or more. Settlements could be reached at any time between now and then. We do not expect Nidek to settle, however. While recognition of the patent is a boost and represents further upside, the quarter's procedure growth numbers are more important in the short term. We expect sequential growth for the quarter to be slightly above our 2% estimate for VISX.